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Objective: In immunocompromised patients with acute respira-
tory failure, invasive mechanical ventilation remains associated 
with high mortality. Choosing the adequate oxygenation strategy 
is of the utmost importance in that setting. High-flow nasal oxygen 
has recently shown survival benefits in unselected patients with 
acute respiratory failure. The objective was to assess outcomes of 
immunocompromised patients with hypoxemic acute respiratory 
failure treated with high-flow nasal oxygen.
Design: We performed a post hoc analysis of a randomized con-
trolled trial of noninvasive ventilation in critically ill immunocompro-
mised patients with hypoxemic acute respiratory failure.
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Setting: Twenty-nine ICUs in France and Belgium.
Patients: Critically ill immunocompromised patients with hypox-
emic acute respiratory failure.
Intervention: A propensity score–based approach was used to 
assess the impact of high-flow nasal oxygen compared with stan-
dard oxygen on day 28 mortality.
Measurements and Main Results: Among 374 patients included 
in the study, 353 met inclusion criteria. Underlying disease 
included mostly malignancies (n = 296; 84%). Acute respiratory 
failure etiologies were mostly pneumonia (n = 157; 44.4%) or 
opportunistic infection (n = 76; 21.5%). Noninvasive ventilation 
was administered to 180 patients (51%). Invasive mechanical 
ventilation was ultimately needed in 142 patients (40.2%). Day 
28 mortality was 22.6% (80 deaths). Throughout the ICU stay, 
127 patients (36%) received high-flow nasal oxygen whereas 
226 patients received standard oxygen. Ninety patients in each 
group (high-flow nasal oxygen or standard oxygen) were matched 
according to the propensity score, including 91 of 180 (51%) 
who received noninvasive ventilation. High-flow nasal oxygen was 
neither associated with a lower intubation rate (hazard ratio, 0.42; 
95% CI, 0.11–1.61; p = 0.2) nor day 28 mortality (hazard ratio, 
0.80; 95% CI, 0.45–1.42; p = 0.45).
Conclusions: In immunocompromised patients with hypoxemic 
acute respiratory failure, high-flow nasal oxygen when compared 
with standard oxygen did not reduce intubation or survival rates. 
However, these results could be due to low statistical power or 
unknown confounders associated with the subgroup analysis. A 
randomized trial is needed. (Crit Care Med 2017; 45:e274–e280)
Key Words: immunosuppression; leukemia; lymphoma; neutropenia; 
noninvasive ventilation; mechanical ventilation
Acute respiratory failure (ARF) remains the first rea-son for admission to ICU in immunocompromised patient (1–3). Various etiologies lead to ARF in that 
setting. Among predictors of outcomes, mechanical venti-
lation remains the major determinant of death (4–7). Thus, 
optimal adequate oxygenation strategy must be selected as 
early as possible, to avoid invasive mechanical ventilation. Fif-
teen years ago, noninvasive ventilation (NIV) was associated 
in decreased need for intubation and reduced mortality (8). 
However, most recent studies did not confirm these results (9). 
Recently, high-flow nasal oxygen (HFNO) has proven benefit 
in unselected patients with hypoxemic ARF. HFNO allowed 
decreasing intubation in the most hypoxemic patient. Further-
more, this device was associated with a significant decrease in 
mortality (10). However, in immunocompromised patients, 
prospective data are lacking. In a retrospective study with 178 
cancer patients with hypoxemic ARF, HFNO plus NIV was 
compared with standard oxygen or NIV alone (11). Although 
intubation rate was not different (47% vs 49%), mortality in 
patients receiving HFNO plus NIV was significantly reduced 
(37% vs 54%; p = 0.027). Last, unlike unselected patients, in 
a prospective multicentric randomized study including 100 
immunocompromised patients with hypoxemic ARF, comfort 
was not improved using HFNO when compared with standard 
oxygen through the Venturi mask (12).
We performed a post hoc analysis of a randomized con-
trolled trial of NIV versus standard oxygen in 374 immuno-
compromised patients admitted to ICU with ARF. The use of 
HFNO was left to clinician’s decision. The aim of the present 
study was to assess the impact of HFNO on the need for intu-
bation and on day 28 (D-28) mortality.
PATIENTS AND METHODS
Data Source
This study is a post hoc analysis of a randomized trial of NIV 
in 374 immunocompromised patients admitted to ICU with 
ARF (9). This trial was prospectively performed between 
August 5, 2013, and January 31, 2015, in 29 ICUs in France and 
Belgium. The study protocol was approved by the French Eth-
ics Committee CPP Ile de France IV Saint Louis (ref number 
2012/11SC). Informed consent was obtained from all patients. 
Exclusion criteria for this study were chronic respiratory fail-
ure, isolated cardiogenic edema, more than one organ failure 
and do-not-intubated order. HFNO could be used as oxygen 
device in the two groups and was not controlled. Data were 
prospectively and daily collected from admission to day 28. 
D-28 mortality was the primary outcome in this study and was 
available for all patients.
Selection of the Study Population for This Post Hoc 
Analysis
Among the 374 patients, those who stayed more than 2 days 
were included in the present analysis. Variables reported in 
tables and figures were collected prospectively. In particu-
lar, we analyzed all data previously identified as associated 
with mortality (underlying disease, performance status in 
the 3 mo from ICU admission, malignancy status [remis-
sion or not], ARF etiology, severity of organ dysfunction), 
and variables previously associated with the need of invasive 
mechanical intubation (oxygen flow at admission and sever-
ity of ARF, i.e., respiratory rate and Spo
2
 at admission and in 
the first three ICU days) (13). Patients were categorized as 
HFNO patients if they had received HFNO within the first 2 
days of ICU admission.
Using pre-established diagnostic criteria (14), investigators 
classified patients as having bacterial pneumonia, cardiac pul-
monary edema, opportunistic pulmonary infections (includ-
ing pneumocystis pneumonia and viral pneumonia), fungal 
pulmonary infections (mostly pulmonary invasive aspergil-
losis), or other ARF etiologies (including drug-related toxic-
ity, infiltration related to hematologic disease, extrapulmonary 
acute respiratory distress syndrome [ARDS], and no definitive 
diagnosis). Patients were deemed to have an undetermined 
ARF etiology when no cause of ARF could be clinically or 
microbiologically documented (14), despite a comprehen-
sive diagnostic workup. Corrected Sequential Organ Failure 
Assessment (SOFAc) score at admission was calculated with-
out the respiratory components of the SOFA score.
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Statistical Analyses
All data are presented as medians (25th–75th percentiles) for 
quantitative variables and frequencies (percentage) for qualita-
tive variables. Baseline characteristics were compared between 
survival and dead patients using Wilcoxon rank-sum test for 
quantitative variables and Fisher exact test for qualitative 
variable.
A propensity score–based approach was used to limit bias 
of between-group comparison to assess the impact of HFNO 
when compared with standard oxygen on D-28 mortality 
(15). The propensity score was defined as the probability that 
a patient with specific baseline characteristics receive HFNO 
trial. Then, two patients with identical propensity score value 
but in the two different treatment groups (HFNO vs standard 
oxygen) can be considered as comparable, and matching on 
the propensity score has been shown as one of the most effi-
cient method for treatment effect assessment (16, 17). We com-
puted the propensity score using logistic regression to predict 
HFNO/standard oxygen group based on baseline characteris-
tics known to be linked to the mortality (underlying disease, 
performance status more than 2 [dependent or bedridden], 
time between hospital and ICU admission, and allogeneic 
stem cell transplantation) (5, 18) and characteristics known to 
be linked to the intubation risk (respiratory rate, Spo
2
, oxy-
gen flow, and number of quadrant involved on chest x-ray at 
admission) and randomization group (NIV or oxygen only) 
(9). Standardized differences are used to compare balance in 
baseline covariates between two HFNO and standard oxygen 
groups (19). A 1:1 matching algorithm without replacement 
was used within a given range of 0.20 sds of the logit of the 
estimated propensity score (15). Final analyses on the matched 
dataset were performed using Cox models with a random effect 
taking into account the paired observations except for ICU-
acquired infection analyzed with a logistic model with random 
effect. Results were presented as hazard ratios or Odds-Ratio 
(OR) with their 95% CI. All tests were two sided at the 0.05 sig-
nificance level. Analyses were performed using R version 3.1.2 
(http://www.R-project.org).
RESULTS
Among 374 patients included in the primary study, 353 
patients who stayed more than 2 days in ICU were included 
in the present analysis (Fig. 1). As shown in Table 1, the main 
underlying disease was cancer (n = 296; 84%), including 157 
active malignancies (45.0%). Time between symptom onset 
and ICU admission was 1 day (0–2 d). Final ARF etiology 
was bacterial infections (n = 152; 43.1%), opportunistic 
infection (n = 76; 21.5), cardiogenic edema (n = 9; 2.5%), 
invasive fungal infection (n = 9; 2.5%), lung involvement by 
the underlying disease (n = 35; 9.9%), drug-related pulmo-
nary toxicity (n = 19; 5.4%), extrapulmonary ARDS (n = 19, 
5.4%), and miscellaneous diagnoses (n = 18, 5.0%). For 16 
patients(4.5%), no diagnosis was determined after a com-
plete diagnostic workup. At least, one investigation was per-
formed for each patient, including bronchoalveolar lavage for 
216 patients (61.5%).
At admission 153 patients(43.3%) needed standard oxy-
gen, at a flow over 9 L/min to maintain a Spo
2
 of 96 (94–98). 
Respiratory rate at admission was 26 (21–30)/min. During 
the first 2 days, 127 patients(35.9%) received HFNO and 226 
patients(64.0%) received standard oxygen. One hundred and 
eighty patients(51%) received NIV sessions. At admission, 
patients in the HFNO group had lower performance status 
than other patients. ARF related to bacterial infections were 
more frequent in the standard oxygen group, whereas invasive 
fungal infections and cardiac pulmonary edema were more 
frequently in the HFNO group (p = 0.005). SOFAc score was 
higher in HFNO group (p = 0.003). NIV tended to be less fre-
quently needed in the HFNO group (p = 0.07). Day-28 mortal-
ity was 22.6% (80 deaths) and was higher in the HFNO group 
than in the standard oxygen group (25.9% versus 20.7%; 
p = 0.23) (Table 1). Overall, invasive mechanical ventilation 
was required in 57 patients (44.9%) from the HFNO group 
and 85 patients(37.6%) from the oxygen group, p = 0.21. 
Among them, overall length of ICU stay was 21 days (17–29 
d). Table 1 describes intubation rate, ICU length of stay, and 
ICU-acquired infection rate in the two groups. Mortality rates 
of intubated patients (49% in HNFO group vs 42%; p = 0.33) 
were not different between the two groups.
One hundred and eighty patients (90 patients in the HFNO 
and 90 in the standard oxygen group) were included in the pro-
pensity analysis (Supplemental Table 1, Supplemental Digital 
Content 1, http://links.lww.com/CCM/C159). Patients were 
not different except for oxygen flows delivered. Particularly 
ARF etiology and characteristic of respiratory failure (respira-
tory rate, Spo
2
 and associated organ failure) at inclusion were 
not different. As shown in Table 2, Figure 2, and Supplemental 
Figure 1 (Supplemental Digital Content 2, http://links.lww.
com/CCM/C160; legend, Supplemental Digital Content 1, 
http://links.lww.com/CCM/C159), impact of HFNO was not 
significant in the matched population for D-28 mortality (haz-
ard ratio [HR] = 0.80 [0.45–1.43]), intubation rate (HR = 0.42 
[0.11–1.61]), ICU length of stay (p = 0.59), or the proportion 
of patients developing ICU-acquired infection (HR = 0.80 
[0.39–1.66]). We performed a sensitivity analysis including 
age that did not modify the results. Furthermore, D-28 mor-
tality of intubated patients was not different between the two 
groups (18 of 40 [45%] in HFNO group vs 19 of 48 [39.6%], 
Figure 1. Patient diagram. HFNC = high-flow nasal cannula. O2 = oxygen.
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TABLE 1.  Patients’ Characteristics and Outcome According to Oxygenation Strategy
Variables
High-Flow Nasal Oxygen Group 
(n = 127)
O2 Group  
(n = 226) p
Baseline characteristics
 Age (yr) m, [interquartile range] 64 [53–72] 63 [52–70] 0.71
 Gender male 85 (67) 124 (55) 0.04
 Underlying disease   0.38
  Acute hematological malignancy 60 (47.2) 94 (41.6)  
  Chronic hematological malignancy 22 (17.3) 43 (19.0)  
  Tumor 30 (23.6) 47 (20.8)  
  Solid organ transplantation 8 (6.3) 16 (7.1)  
  Other immunosuppression 7 (5.5) 26 (11.5)  
 Allogenic stem cell transplantation 17 (18.8) 17 (18.9) 0.74
 Performance status > 2 (severely disabled or bedridden) 43 (47.7) 35 (38.8) <0.001
 Delay from respiratory symptoms to ICU admission (d) 1 [0–2] 1 [0–2] .04
 Neutropenia at admission 22 (28.2) 25 (33.3) 0.76
 Acute respiratory failure etiology   0.005
  Infection 51 (40.1) 101 (44.7)  
  Cardiogenic edema 2 (1.6) 7 (3.1)  
  Opportunistic infection 27 (21.2) 49 (21.6)  
  Fungal infection 7 (5.5) 2 (0.9)  
  Othera 40 (31.4) 67 (29.6)  
 Maximum respiratory rate at day 1 26 [21–30) 25 [21–30] 0.5
 Maximum O2 flow at day 1 40 [15–50] 5 [4–9] <0.001
 Minimum Spo2 at day 1 96 [93–97] 96 [94–98] 0.09
 Noninvasive ventilation at day 1 56 (44) 124 (55) 0.07
 Shock at day 1 21 (16) 32 (14) 0.66
 Acute kidney injury at day 1 38 (30) 71 (31) 0.92
 SOFA score at day 1 without respiratory 3 [1–5] 4 [2–6] 0.003
 SOFA    
 Bronchoalveolar lavage during ICU 47 (37) 88 (39) 0.76
 Outcome    
  Intubation throughout the ICU stay 57 (44.9) 85 (37.6) 0.21
  Duration of mechanical ventilation 13 [4–46] 17 [7–33] 0.13
  ICU length of stay 8 [5–16] 5 [2–40] 0.05
  ICU-acquired infection 29 (22.8) 64 (28.3) 0.13
  D-28 mortality 33 (25.9) 47 (20.7) 0.23
  D-28 mortality of intubated patients 28/57 (49) 36/85 (42) 0.33
D-28 = day 28, SOFA = Sequential Organ Failure Assessment.
a Drug-related toxicity, infiltration related to hematologic disease, extrapulmonary acute respiratory distress syndrome, and no definitive diagnosis.
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odds ratio = 1.24 [0.53–2.92]; p = 0.61). Intubation rate and 
mortality according with the oxygenation strategy is described 
in Supplemental Figure 2 (Supplemental Digital Content 3, 
http://links.lww.com/CCM/C161; legend, Supplemental Digital 
Content 1, http://links.lww.com/CCM/C159).
DISCUSSION
ARF is the leading cause for ICU admission in patients with 
hematological malignancies. Mortality of patients requiring 
mechanical ventilation remains high (5, 7, and 20), and every 
strategy that avoids intubation should be given priority. Previous 
studies have demonstrated benefits from NIV in immunocom-
promised patients with ARF at a time where mortality associ-
ated with mechanical ventilation was up to 80% (8). In more 
recent studies with lower mortality rates, NIV benefits could 
not be evidenced anymore (9). Recently, with the evidence that 
a new oxygen device as HFNO was associated with a decreased 
need of intubation in the most hypoxemic patients and reduced 
mortality rates in unselected critically ill patients with ARF, it 
is logical to establish whether or not these benefits extend to 
immunocompromised patients (10). In this study, including 
various types of immunocompromised patients, and analyzing 
only patients who received HFNO more than 2 days, HFNO was 
not associated with any significant benefits.
Interestingly, patients managed in this study have simi-
lar severity at ICU admission than those reported in previ-
ous studies (5, 20, 21). Also, even though intubation rate was 
similar when compared with that in earlier reports, mortality 
was lower (22% vs over 40%) than in previous studies, shed-
ding light on continuing improvements in this population, 
even when patients are at high risk of receiving mechanical 
ventilation (5, 14, 22–25). Along this line, the use of ICU was 
made earlier in these patients (i.e., 1 d [0–2 d] after respira-
tory symptoms onset), as compared to previous studies (5, 26). 
Last, one may advocate that reported mortality rates are biased 
by inclusion and exclusion criteria that excluded patients with 
shock. However, the fact that patients with cardiac pulmonary 
edema for whom reported mortality is constantly lower, were 
also excluded may balance this bias (22, 27).
The research question pertaining to this study is whether or 
not ventilation strategy per se could have significant impact on 
outcomes. On the one hand, avoiding invasive mechanical ven-
tilation and its complications carries obvious benefits. On the 
other hand, mortality of intubated patients has much decreased, 
whereas other determinants of mortality are still heavily impact-
ful. Namely, delay in ICU management, ability to identify ARF 
etiology, invasive fungal infections, associated organ dysfunc-
tions, and being allogeneic bone marrow transplant recipient are 
strongly associated with mortality (5, 18, 28). Whether initial oxy-
genation strategy might overcome these strong predictors of out-
comes remains unclear. Unlike the Florali study (10) that mostly 
included unselected patients with community-acquired pneumo-
nia, this study confirms that immunocompromised patients pres-
ent with a wide spectrum of ARF etiology and that one strategy 
may not fit to all. Hence, the lack of benefit from HFNO may be 
TABLE 2. Primary and Secondary Outcomes According to Oxygenation Strategy in the 
Matched Population
 
High-Flow Nasal  
Oxygen Group (n = 90)
O2 Group  
(n = 90)
Hazard Ratio  
95% CI p
Primary endpoint     
 All cause 28-d mortality 21 (23.3%) 23 (25.5%) 0.80 (0.45–1.43) 0.45
Secondary endpoints     
 Need for invasive mechanical ventilation 40 (44.4%) 48 (53.3%) 0.42 (0.11–1.61) 0.20
 Duration of mechanical ventilation 13 [4–46] 16 [8–33]  0.32
 ICU-acquired infection 21 (23.3%) 28 (31.1%) 0.80 (0.39–1.66) 0.55
 Length of ICU stay 8 [5–16] 8 [3–29]  0.59
 Length of hospital stay 24 [14–51] 32 [19–52]  0.25
Figure 2. Probability of survival of the risk of day-28 mortality. Kaplan-Meier 
estimates of the probability of day-28 mortality in immunocompromised 
patients with acute respiratory failure receiving either high-flow nasal 
oxygen (HFNO) or oxygen. HFNO (black line), oxygen group (gray line).
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ascribable to a lack of adjustment on these important confound-
ers, raising concerns on any generalizability of available data, and 
warranting dedicated trials in this specific population. Putting 
together these data and those from our NIV trial, we remind that 
delayed intubation had been associated with increased mortality 
in immunocompromised patients (26, 29, 30).
In keeping with our data, most of ARF etiologies were related 
to infections, a situation associated with higher mortality (22, 
27, 31). Although mortality rate was low in our study, intubation 
rate in the matched population was over 40%, which depicts 
severe conditions. Furthermore less than 5% of patients remain 
without diagnosis of ARF. This proportion was lower than that 
of previous studies and was known to be associated with higher 
mortality rate (14, 23). This low mortality rate could be related 
to the admission of these patients in ICUs that are used to take 
care of immunocompromised patients with ARF (32).
This study has several limitations. First, this is a post hoc 
analysis of a prospective trial performed to demonstrate benefits 
from early NIV in immunocompromised patients with ARF (9). 
Nevertheless, randomization group was included in the propen-
sity score and NIV may not have modified results. However, in 
a recent retrospective single-center study, treatment with NIV 
and HFNO was associated with a better survival in malignancy 
patients with ARF (11). Second, the decision to offer HFNO to 
ARF patients was left to physician in charge. Even though cen-
ters participating to this study have large experience of dealing 
with immunocompromised patients, no proper HFNO protocol 
was applied in this study. Furthermore, the study was performed 
before the HNFO trial was published (10). Thus, no standardized 
protocol for HFNO was described in the study. This was the most 
important weakness of this post hoc study. This propensity anal-
ysis with a matching procedure ensured to be as close as possible 
to a randomized clinical trial by selecting patients with compa-
rable characteristics. For example, ARF etiologies were included 
in the matching procedure to consider length of pulmonary 
symptoms and severity of ARF in the propensity score. A trial to 
demonstrate survival benefits from HFNO comparing to oxygen 
remains warranted. Third, only 180 patients were included in the 
propensity analysis. This sample could be seen as small, but it was 
nearly as important as the sample in Florali study (106 patients in 
HNFC group vs 94 patients in oxygen group) (10). Furthermore 
this study was the most important in immunocompromised 
patients with ARF where mortality is higher than other patients.
In conclusion, in this post hoc analysis with immunocom-
promised patients and hypoxemic ARF, HFNO when com-
pared with the standard oxygen did not reduce intubation 
or survival rates. However, these results could be due to low 
statistical power or unknown confounders associated with the 
subgroup analysis, a randomized trial is needed.
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